Related Experiment Videos
Discovery of a novel Raf kinase inhibitor
J F Lyons1, S Wilhelm, B Hibner
1Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94806, USA. jlyons1@ireland.com
Endocrine-Related Cancer
|September 22, 2001
Summary
This study explores Ras signal transduction and mutations, identifying Raf kinase as a therapeutic target. The development of BAY 43-9006, a novel Raf kinase inhibitor, demonstrates potential for selective anti-tumor activity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ras signal transduction pathways are crucial in cellular processes.
- Ras mutations are linked to various diseases, highlighting their oncogenic potential.
- Understanding Ras effector pathways, like the RAF/MEK/ERK cascade, is key for targeted therapies.
Purpose of the Study:
- To provide background on Ras biology and mutation epidemiology.
- To validate Raf kinase as a therapeutic target.
- To outline the development of a novel Raf kinase inhibitor, BAY 43-9006.
Main Methods:
- Review of Ras signal transduction and mutation epidemiology.
- Genetic validation of targets within the Ras signaling cascade.
- Pre-clinical development of the Raf kinase inhibitor BAY 43-9006.
Main Results:
- Raf kinase identified as a viable therapeutic target based on studies of cell lines with mutant MEK.
- BAY 43-9006 demonstrates selective anti-tumor activity in pre-clinical development.
- The drug discovery program successfully targeted Raf kinase activity.
Conclusions:
- Targeting Raf kinase offers a promising strategy for cancer therapy.
- BAY 43-9006 represents a significant advancement in the development of Raf kinase inhibitors.
- Further pre-clinical development of BAY 43-9006 is warranted.